SAN DIEGO--(BUSINESS WIRE)-- Neuropore Therapies, Inc. announced today that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence. The molecular targets of interest are implicated in dysfunctions in proteostasis and can therefore be modulated to restore normal cellular protein clearance mechanisms. The collaboration aims to discover small molecule therapeutics for multiple targets.
Errol De Souza, President and CEO of Neuropore, stated, “We are very excited to establish this collaboration with BenevolentAI. The application of artificial intelligence to the elaboration of novel approaches to medicine is one of the leading edges of science and is an approach that is bound to lead to new discoveries. Neuropore’s Autophagy Platform is a perfect testing ground for new hypotheses and discoveries. In addition to its drug discovery capabilities, Neuropore’s development and translational experience in degenerative disease makes it a great fit for both companies.”
Anne Phelan, SVP BenevolentAI, said, “The collaboration between Neuropore and BenevolentAI offers a fantastic opportunity to accelerate the discovery of new medicines. Neuropore has built a world-leading platform for experimentally evaluating key processes within protein homeostasis, a critical biological mechanism in neurodegenerative diseases such as ALS. This system will allow the rapid and thorough evaluation of multiple novel targets, discovered using the BenevolentAI Platform, and enable us to validate new targets faster than ever."
Neuropore Therapies, Inc. is a San Diego, California based biopharmaceutical company developing novel disease modifying small molecule therapeutics for the treatment of neurodegenerative disorders. Neuropore’s therapeutic candidates block the neurotoxic oligomeric aggregates of misfolded proteins which are the primary drivers of disease pathology by preventing the induction of damaging neuroinflammation mechanisms common to many neurodegenerative disorders. By targeting the underlying mechanisms by which neuroinflammation drives a vicious cycle of protein pathology and neurodegeneration, Neuropore’s therapeutic candidates may have broad applications in slowing disease progression and improving symptoms across a wide range of neuro-inflammatory / neuro-degenerative disorders.
For more information visit www.neuropore.com.
BenevolentAI, founded in 2013, is an AI company developing and applying advanced technologies to accelerate the journey from data to medicine. The company combines the power of computational medicine and advanced AI with the principles of open systems and cloud computing to transform the way drugs are designed, developed, tested and brought to market. The company has developed the ‘Benevolent Platform’, the world’s only end-to-end computational and experimental platform for drug discovery that spans data ingestion to clinical development.
BenevolentAI is HQ’d in London with a research facility in Cambridge (UK) and further offices in New York and Belgium. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson’s, Ulcerative Colitis and Sarcopenia.
This press release contains forward-looking statements based on current information, projections and assumptions of management. Statements in this press release that are not strictly historical in nature are forward-looking statements. By their nature forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements contained in this press release.
Important factors that could result in such differences include the risks and uncertainties inherent in drug discovery, development, approval and commercialization, collaborations with others, and the fact that past results of clinical trials and regulatory decisions may not be indicative of future trial results or regulatory decisions.
